XML 69 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations (Tables)
 9 Months Ended
Sep. 30, 2013
Balance Sheet [Member] | Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):
Cash
$
195.1

Prepaid expenses and other current assets
14.9

Property, plant and equipment, net
1,023.7

Other Assets
330.5

Accounts payable
(177.1
)
Accrued liabilities
(79.2
)
Accumulated comprehensive income
(169.9
)
Loss on exit of segment
$
1,138.0
Balance Sheet [Member] | Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The Company recognized the following loss on the date of sale of its 51% interest in Erye on November 13, 2012 (in thousands):
Fair value of consideration received
$
13,397.9

Carrying value of segment non-controlling interest
6,015.0

Carrying value of segment accumulated comprehensive income
4,387.4

 
$
23,800.3

Less carrying amount of assets and liabilities sold:
 
Cash
$
8,457.5

Restricted Cash
2,918.1

Accounts Receivable
6,130.2

Inventories
15,077.7

Prepaid expenses and other current assets
957.8

Property, plant and equipment, net
38,102.0

Other assets
5,946.3

Accounts payable
(9,604.8
)
Accrued liabilities
(2,008.8
)
Bank loans
(15,133.5
)
Notes payable
(6,599.3
)
Other liabilities
(9,166.8
)
Amount due related party
(7,859.7
)
 
$
(27,216.7
)
 
 
Loss on exit of segment
$
(3,416.4
)
Income Statement [Member] | Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The operating results of the Regenerative Medicine – China business for the nine months ended September 30, 2012, which are included in discontinued operations, were as follows (in thousands):
 
Nine Months Ended September 30, 2012
Revenue
$
52.3

Cost of revenues
(30.6
)
Research and development
(103.3
)
Selling, general, and administrative
(497.3
)
Other income (expense)
(6.8
)
Loss on exit of segment
(1,138.0
)
Loss from discontinued operations
$
(1,723.7
)
Income Statement [Member] | Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The operating results of the Pharmaceutical Manufacturing - China business for the three and nine months ended September 30, 2012, including the estimated asset impairments based on the definitive agreement purchase price as of September 30, 2012, were as follows (in thousands):
 
Three Months Ended September 30, 2012
 
Nine Months Ended September 30, 2012
Revenue
$
20,036.4

 
$
57,254.7

Cost of revenues
(11,551.5
)
 
(37,131.5
)
Research and development
(611.8
)
 
(2,231.5
)
Selling, general, and administrative
(3,514.7
)
 
(9,714.8
)
Other expense
(0.9
)
 
(1,008.3
)
Provision for income taxes
(1,029.9
)
 
(1,535.4
)
Asset impairments
(3,175.5
)
 
(31,170.1
)
Loss on sale of segment
—

 
—

Loss from discontinued operations
$
152.1

 
$
(25,536.9
)